SC
RDY icon

Stance Capital’s Dr. Reddy's Laboratories RDY Stock Holding History

Stance Capital’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,528
Closed -$21.2K – 401
2026
Q1 		$21.2K Buy
+1,528
New +$21.3K 0.01% 210

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Stance Capital's RDY Position: Q2 2026 in Review

Stance Capital sold out of Dr. Reddy's Laboratories (RDY) in Q2 2026, closing a stake of 1,528 shares — an estimated $21.2K sold.

Stance Capital first reported a position in RDY in Q1 2026 and held it in 1 quarter. The position peaked at $21.2K in Q1 2026. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

  • Stance Capital reported no remaining Dr. Reddy's Laboratories position as of Q2 2026 after selling out during the quarter.
  • Stance Capital sold 1,528 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $21.2K.
  • Stance Capital first reported a position in Dr. Reddy's Laboratories in Q1 2026 and held it in 1 quarter.
  • Stance Capital's Dr. Reddy's Laboratories position peaked at $21.2K in Q1 2026.
  • 238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Stance Capital's 13F filing for Q2 2026, filed 14 Aug 2026.